The first synthetic analogue of α-GalCer (KRN7000) was first shown to exhibit NK-mediated anti-tumor effects (8), then shown to be a CD1d-restricted antigen for iNKT cells (9, 10). The gene discussed is CD1D; the disease is neoplasm.